Noom

Great to see Athletech News spotlight Noom's latest GLP-1 Companion app findings 🔎 Reporter Courtney R. points out, "The question is no longer whether the drugs work, but why some patients see better results and remain engaged with treatment longer than others." As Noom CEO Geoff Cook shared, we believe "GLP-1 is a catalyst for change," and our data suggests that engagement with our Companion app alongside GLP-1 therapy may help support better long-term outcomes. Full coverage: https://bit.ly/4qkw6FM

New real-world findings from Noom: 𝐄𝐧𝐠𝐚𝐠𝐞𝐦𝐞𝐧𝐭 𝐰𝐢𝐭𝐡 𝐨𝐮𝐫 𝐆𝐋𝐏-𝟏 𝐂𝐨𝐦𝐩𝐚𝐧𝐢𝐨𝐧 𝐚𝐩𝐩 𝐢𝐬 𝐥𝐢𝐧𝐤𝐞𝐝 𝐭𝐨 𝐛𝐞𝐭𝐭𝐞𝐫 𝐡𝐞𝐚𝐥𝐭𝐡 𝐨𝐮𝐭𝐜𝐨𝐦𝐞𝐬. In our largest-ever analysis of Noom’s GLP-1 Companion app, members who engaged more frequently with the app: ✅ Lost 25.2% more weight on average by week 40 (an additional 8.3 lbs compared with the least-engaged members) ✅ Stayed on their medication program 2.2x longer within the first 12 months The takeaway? Pairing GLP-1s with our engaging Companion app may help support sustained progress. Read the full report: https://bit.ly/49Wfz6a

We're honored to debut on Newsweek's Most Trusted Brands 2026 list ✨ The article highlights how Noom continues to evolve - from habit science and GLP-1 support to biomarker testing and ongoing research - all in service of empowering everyone, everywhere to live better, longer every day. Read the article featuring Noom CEO Geoff Cook: https://bit.ly/3M9Wkge

🧠 𝐏𝐫𝐞𝐯𝐞𝐧𝐭𝐢𝐯𝐞 𝐦𝐞𝐝𝐢𝐜𝐢𝐧𝐞 𝐢𝐬𝐧’𝐭 𝐚 𝐭𝐫𝐞𝐧𝐝…𝐢𝐭’𝐬 𝐭𝐡𝐞 𝐟𝐮𝐭𝐮𝐫𝐞 𝐨𝐟 𝐡𝐞𝐚𝐥𝐭𝐡𝐜𝐚𝐫𝐞. At Noom, this belief has always been foundational to our mission - yet most healthcare systems still operate reactively, stepping in only after symptoms appear. In this new piece for the World Economic Forum Annual Meeting, Noom Co-Founder and Executive Chairman Saeju Jeong explores why this model is failing, and how a shift toward early action and personalization can usher in a new era of longevity. Read the full blog: https://bit.ly/49JVz5m #WEF26

This week at J.P. Morgan Healthcare Week in San Francisco, Noom CEO Geoff Cook joined a panel hosted by Evidation on "GLP-1s in the Wild" - what these therapies look like in real life, and where the category is headed. Geoff spoke alongside: - Lindsay Holden, Baseline Therapeutics Center for Addiction Science Policy & Research - Jamie Coleman, Kailera Therapeutics - Rachel Sha, Vaxess Technologies Moderated by Phil Johnson, Evidation. Geoff shared the following insights with the panel: 𝟭. 𝗠𝗶𝗰𝗿𝗼𝗱𝗼𝘀𝗶𝗻𝗴 = 𝗮𝗻 𝗮𝗰𝗰𝗲𝘀𝘀 + 𝘁𝗼𝗹𝗲𝗿𝗮𝗯𝗶𝗹𝗶𝘁𝘆 𝘂𝗻𝗹𝗼𝗰𝗸 Cost, side effects, and discontinuation are real barriers for GLP-1 use. Microdosing may help expand who can benefit - and stay on therapy. 𝟮. 𝗚𝗟𝗣-𝟭𝘀 𝘄𝗼𝗿𝗸 𝗯𝗲𝘀𝘁 𝘄𝗵𝗲𝗻 𝗽𝗮𝗶𝗿𝗲𝗱 𝘄𝗶𝘁𝗵 𝗯𝗲𝗵𝗮𝘃𝗶𝗼𝗿 𝗰𝗵𝗮𝗻𝗴𝗲 Medication can be a catalyst, but without habit support, people can run into problems like losing weight without protecting muscle. 𝟯. 𝗚𝗟𝗣-𝟭 + 𝗺𝗶𝗻𝗱𝗳𝘂𝗹𝗻𝗲𝘀𝘀 𝗺𝗮𝘆 “𝗾𝘂𝗶𝗲𝘁” 𝗺𝗲𝗻𝘁𝗮𝗹 𝗻𝗼𝗶𝘀𝗲 Both GLP-1s and mindfulness practices may dampen the mental chatter that makes habits hard to form - creating more space for intentional choices. 𝟰. 𝗧𝗵𝗲 𝘀𝘁𝗼𝗿𝘆 𝗶𝘀 𝗺𝗼𝘃𝗶𝗻𝗴 𝗯𝗲𝘆𝗼𝗻𝗱 𝘄𝗲𝗶𝗴𝗵𝘁 Emerging frontiers for GLP-1 therapy include treating inflammation, pain, and addiction. Take a look at some photos from the event!

✨ Noom’s Chief Wellness Ambassador Rebel Wilson stopped by the TODAY Show this morning with Jenna Bush Hager and Matt Rogers, sharing insights from her health journey, exciting life updates, and a fun round of Fact or Fake. Catch the inspiring conversation: https://bit.ly/452EOAO

This week, Noom convened leaders across academia, healthcare, and the arts at our inaugural Art of Wellbeing Summit, hosted at the Princeton University Art Museum ✨ Speakers shared latest insights on healthy aging, AI and longevity, music and the arts, women's health and sexual health, nutrition, and more. Panel discussions explored the role of creativity, psychology, and science in helping people live better, longer lives. Couldn’t make the full event? 🎥 Watch the recap here: https://lnkd.in/gy26GhH4 (Thank you to our incredible speakers: James Pawelski, Rebel Wilson, Christina Economos, Erik Nook, Elizabeth Margulis, Coleen Murphy, Valery Yakubovich, David G. Stork, Tamsen Fadal, Maria Sophocles, Sasha Samuels, Veronica Maria White, Geoff Cook, Jeffrey Egler, Aaron Severs, Richard Friedman, Karen Mann MD, Erin Owen, PhD, MPH, Myles Johnson, Madeline Cook, Daniel Zahler)

We’re live now at the Art of Wellbeing Summit 🎥 Tune in to hear real-time insights from leaders across academia, healthcare, and the arts, coming together to reimagine what wellbeing can look like today and in the future. Watch the live stream here: bit.ly/3Nkwjel

Tomorrow, we go live with Noom’s Art of Wellbeing Summit. ✨ Join us for conversations with leading voices across academia, healthcare, and the arts as we explore how science, psychology, and creativity intersect to support longer, healthier, and more meaningful lives. Register for the free stream and explore the full agenda: https://lnkd.in/gxi3JtHb

What does the evolving GLP-1 landscape mean for preventive health? In this episode of Boundless Life, Noom CEO Geoff Cook joins Ben Greenfield to break down key considerations, including: 🧬 What it really means to microdose a GLP-1 🧠 How pairing low-dose medication with behavior change can support long-term outcomes 🧪 Which biomarkers matter most for tracking progress ✨ And much more Listen to the episode: https://bit.ly/4pmIQeH